Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
18 papers
Recent·Most cited
M. McCallum, Y.-J. Park, C. Stewart, K. R. Sprouse, J. Brown, M. A. Tortorici, C. Gibson, E. Wong, M. Ieven, A. Telenti, D. Veesler
This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.
Cell · Aug 1, 2024Peer-reviewedBiochemistry
M. Rexhepaj, Y.-J. Park, L. Perruzza, D. Asarnow, M. McCallum, K. Culap, C. Saliba, G. Leoni, A. Balmeli, C. Yoshiyama, M. S. Dickinson, J. Quispe, J. T. Brown, M. A. Tortorici, K. R. Sprouse, , D. Veesler
The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.
bioRxiv · Mar 27, 2024 · PreprintBiochemistry
M. A. Tortorici, A. Addetia, A. J. Seo, J. Brown, K. Sprouse, J. Logue, E. Clarke, N. Franko, H. Chu, D. Veesler
This study shows that immune imprinting from prior Wuhan-Hu-1 spike exposure persists after XBB.1.5 vaccine booster, with neutralizing antibodies dominated by pre-existing memory B cells.
bioRxiv · Nov 28, 2023 · PreprintImmunology
C.-B. Ma, C. Liu, Y.-J. Park, J. Tang, J. Chen, Q. Xiong, J. Lee, C. Stewart, D. Asarnow, J. Brown, M. A. Tortorici, X. Yang, Y.-H. Sun, Y.-M. Chen, X. Yu, , H. Yan
The paper identifies two European bat MERS-related coronaviruses that use ACE2 as their receptor, revealing a distinct binding mode and host tropism determinants.
bioRxiv · Oct 2, 2023Microbiology
R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli
The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.
bioRxiv · Sep 30, 2022Immunology
J. S. Low, J. Jerak, M. A. Tortorici, M. McCallum, D. Pinto, A. Cassotta, M. Foglierini, F. Mele, R. Abdelnabi, B. Weynand, J. Noack, M. Montiel-Ruiz, S. Bianchi, F. Benigni, N. Sprugasci, , F. Sallusto
The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.
bioRxiv · Mar 30, 2022Immunology
J. E. Bowen, A. C. Walls, A. Joshi, K. R. Sprouse, C. Stewart, M. A. Tortorici, N. M. Franko, J. K. Logue, I. G. Mazzitelli, S. W. Tiles, K. Ahmed, A. Shariq, G. Snell, N. T. Iqbal, J. Geffner, , D. Veesler
This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.
bioRxiv · Dec 19, 2021 · PreprintImmunology
M. A. Tortorici, A. C. Walls, A. Joshi, Y.-J. Park, R. T. Eguia, T. Stevens-Ayers, M. J. Boeckh, A. Talenti, A. Lanzavecchia, D. Corti, J. D. Bloom, D. Veesler
The paper determines the structure of the CCoV-HuPn-2018 spike glycoprotein, identifies its receptor, and shows cross-neutralizing antibodies against related coronaviruses.
bioRxiv · Oct 25, 2021Microbiology
D. Pinto, M. M. Sauer, N. Czudnochowski, J. S. Low, M. A. Tortorici, M. P. Housley, J. Noack, A. C. Walls, J. E. Bowen, B. Guarino, L. E. Rosen, J. di Iulio, J. Jerak, H. Kaiser, S. Islam, , Lanzave
This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.
bioRxiv · May 9, 2021 · PreprintImmunology
M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom
This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.
bioRxiv · Apr 7, 2021 · PreprintImmunology
M. McCallum, J. Bassi, A. De Marco, A. Chen, A. C. Walls, J. Di Iulio, M. A. Tortorici, M.-J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, , D. Veesler
This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.
bioRxiv · Mar 31, 2021 · PreprintImmunology
A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler
This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.
bioRxiv · Mar 15, 2021Immunology
M. McCallum, A. De Marco, F. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, , D. Veesler
The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.
bioRxiv · Jan 14, 2021Immunology
M. Sauer, Y.-J. Park, M. A. Tortorici, A. C. Walls, L. Homad, O. Acton, J. E. Bowen, C. Wang, X. Xiong, W. de van der Schueren, J. Quispe, B.-J. Bosch, B. G. Hoffstrom, A. T. McGuire, D. Veesler
This study identifies a monoclonal antibody that broadly neutralizes multiple beta-coronaviruses by targeting a conserved epitope, providing a structural basis for designing pan-coronavirus vaccines.
bioRxiv · Dec 29, 2020Biochemistry
T. N. Starr, A. J. Greaney, S. K. Hilton, K. H. Crawford, M. J. Navarro, J. E. Bowen, M. A. Tortorici, A. C. Walls, D. Veesler, J. D. Bloom
The paper experimentally measures the effects of all amino-acid mutations in the SARS-CoV-2 RBD on protein folding and ACE2 binding, identifying constrained regions and tolerated mutations.
bioRxiv · Jun 17, 2020Microbiology
K. H. D. Crawford, R. Eguia, A. S. Dingens, A. N. Loes, K. D. Malone, C. R. Wolf, H. Y. Chu, M. A. Tortorici, D. Veesler, M. Murphy, D. Pettie, N. P. King, A. B. Balazs, J. D. Bloom
This paper provides a protocol for pseudotyping lentiviral particles with SARS-CoV-2 Spike protein to measure neutralizing antibody activity in a luciferase-based assay.
bioRxiv · Apr 20, 2020Microbiology
D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti
This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.
bioRxiv · Apr 7, 2020Immunology
A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, D. Veesler
This study characterizes the structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein, showing its receptor-binding properties, furin cleavage site, and potential for cross-neutralizing antibodies.
bioRxiv · Feb 19, 2020Biochemistry